Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
Bernhard T. Baune, Kevin Rosemann, Dimitri Hefter, Mustafa Tonkul, Erhan Kavakbasi
BMC Psychiatry March 17, 2026 DOI: 10.1186/s12888-026-07980-8 via PubMed Central
Summary
AI-generated from the abstractIn real-world clinical settings, intranasal esketamine shows effectiveness for treatment-resistant depression, with response varying based on patient characteristics. The text describes factors associated with treatment response but does not specify which factors or provide concrete numbers.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression receiving intranasal esketamine in real-world clinical practice |
| Intervention | Intranasal esketamine |
| Citations | 2 |
| Key finding | Intranasal esketamine is effective in real-world treatment of treatment-resistant depression, with response influenced by patient-specific factors. |
Abstract
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.